Skip to Content

Join the 'Hodgkin's Lymphoma' group to help and get support from people like you.

Hodgkin's Lymphoma News

Related terms: Cancer, Hodgkin's Lymphoma, Hodgkin's Disease, Lymphoma, Hodgkin's

Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

Posted 3 days ago by

PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.1 This approval will provide health care ...

Get Active, Beat Lymphoma?

Posted 12 Dec 2017 by

TUESDAY, Dec. 12, 2017 – Physical activity appears to help people with lymphoma survive their disease. That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection. "As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but ...

Childhood Cancer Survivors Now Living Healthier Lives

Posted 2 Jun 2017 by

FRIDAY, June 2, 2017 – For people who battled cancer in childhood, the prospects for a long life without cancer recurrence or chronic illness are better than ever, a new study finds. That's largely due to changes in cancer treatment protocols that have meant less toxicity to children and less chance for long-term side effects, researchers said. This is the first "comprehensive" study on the ...

FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)

Posted 15 Mar 2017 by

KENILWORTH, N.J. March 14, 2017 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have r ...

Hodgkin Lymphoma Survivors Face Risk of Second Cancer: Study

Posted 13 Mar 2017 by

MONDAY, March 13, 2017 – The risk of developing a second type of cancer may be high among Hodgkin lymphoma survivors, especially those with a family history of cancer. That's the finding of a new European study in which researchers examined data from more than 9,500 Hodgkin lymphoma patients. Hodgkin lymphoma, once known as Hodgkin's disease, is a cancer that starts in the white blood cells ...

Health Highlights: March 13, 2017

Posted 13 Mar 2017 by

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Consumer Advocates Pan Trump's Choice for FDA Head A former top official in the U.S. Food and Drug Administration during the administration of President George W. Bush is President Donald Trump's choice to lead the agency. The nomination of Scott Gottlieb, 44, was welcomed by drug industry ...

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study ...

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of ...

Scans May Spare Some Hodgkin Lymphoma Patients From Chemo

Posted 23 Jun 2016 by

THURSDAY, June 23, 2016 – A certain type of medical scan can be used to help spare some Hodgkin lymphoma patients from the severe side effects of chemotherapy, a new study suggests. Researchers found that PET imaging can identify patients whose Hodgkin lymphoma will likely respond better to treatment, and therefore require less intensive chemotherapy. "The good news is that the majority of ...

Opdivo (nivolumab) FDA Approved for the Treatment of Hodgkin Lymphoma

Posted 18 May 2016 by

PRINCETON, N.J., May 17, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 ...

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

Posted 16 May 2016 by

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries. There is no indication at this time that counterfeit BiCNU has entered the legitimate U.S. drug supply chain and no indication that any U.S. patients have received counterfeit BiCNU. See the FDA Alert ...

Young Black, Hispanic Hodgkin Lymphoma Patients Face Worse Outcomes: Study

Posted 3 Feb 2016 by

WEDNESDAY, Feb. 3, 2016 – Hodgkin lymphoma is a form of cancer that starts in white blood cells is often curable. But, poor black and Hispanic young people are less likely to survive the disease than their white peers, a new study shows. "This study identifies vulnerable subgroups of young Hodgkin lymphoma patients at higher risk of dying from their disease, and points to disparities in ...

Lymphoma Survivors May Not Get All Recommended Follow-Up Care

Posted 15 Jan 2016 by

FRIDAY, Jan. 15, 2016 – Some teen and young adult survivors of Hodgkin lymphoma do not receive all the recommended follow-up care, a new study finds. The study included 354 survivors in California who were diagnosed between ages 15 and 39, and followed for an average of six years. Within the first year, 52 percent of the survivors did not receive all recommended care outlined in the National ...

Fewer Childhood Cancer Survivors Dying From 'Late' Effects

Posted 13 Jan 2016 by

WEDNESDAY, Jan. 13, 2016 – Fewer childhood cancer survivors are dying years later from lingering effects of the treatment that conquered their cancer, a new study finds. Experts called the report, published in the Jan. 14 issue of the New England Journal of Medicine, "very good news." "The findings substantiate what experts in the field have hoped would be true," said lead researcher Dr. Gregory ...

Childhood Cancer Tied to Raised Risk for Other Ills in Adult Life

Posted 11 Nov 2015 by

WEDNESDAY, Nov. 11, 2015 – Childhood cancer survivors are at increased risk for diabetes and other autoimmune diseases, a new study suggests. "Cure is no longer a sufficient goal in childhood cancer care," the researchers wrote. "As the vast majority of these patients survive, attention must be paid to their long-term quality of life and health challenges." In the study, the investigators ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups


Related Drug Support Groups

methotrexate, Opdivo, Keytruda, Cytoxan, cyclophosphamide, nivolumab, doxorubicin, Leukeran, vincristine, view more... pembrolizumab, Adriamycin, etoposide, vinblastine, Neosar, Adcetris, Velban, DTIC-Dome, Oncovin, bleomycin, chlorambucil, Blenoxane, brentuximab, carmustine, Adriamycin RDF, dacarbazine, Gleostine, lomustine, Adriamycin PFS, procarbazine, Cytoxan Lyophilized, Gliadel, Vincasar PFS, Matulane, CeeNU, Toposar, Etopophos, VePesid, BiCNU, Bleo 15k